Self-delivery nanomedicine for vascular disruption-supplemented chemo-photodynamic tumor therapy

Tumor vascular blockade is a promising strategy for adjuvant cancer treatment. In this work, a selfdelivery nanomedicine is developed based on a vascular disruptor and photosensitizer for tumor synergistic therapy. Specifically, this nanomedicine (designated as CeCA) is comprised of combretastatin A4 (CA4) and chlorine e6 (Ce6) by self-assembly technique. Among which, CA4 could not only induce tubulin inhibition for chemotherapy but also disrupt the vasculature to cause tumor hemorrhage. Moreover, Ce6 is able to generate lots of singlet oxygen (1O2) for synergistic photodynamic therapy (PDT) under light irradiation. It is interesting that the carrier-free CeCA possessed a favorable stability and an improved cellular uptake behavior. After intravenous administration, CeCA prefers to accumulate at tumor site for vascular disruption-supplemented chemo-photodynamic therapy. Notably, CeCA is prepared without additional carriers, which avoids the system toxicity raised by excipients. Consequently, CeCA greatly inhibits the tumor growth and leads to a low side effect in vivo. It might open a window in the development of self-supplementary nanomedicine for synergistic tumor treatment. (c) 2021 Elsevier Inc. All rights reserved.

Automated summary

A self-delivery nanomedicine based on a vascular disruptor and photosensitizer has been developed for synergistic tumor therapy. This nanomedicine can inhibit tumor growth through chemotherapy and photodynamic therapy, with low side effects in vivo.